PT-141
Also known as: Bremelanotide, Rekynda, Vyleesi
3 notable studies · 4 references
TLDR
Bremelanotide (PT-141) is a synthetic cyclic melanocortin agonist developed from Melanotan II research that acts primarily through central melanocortin signaling and has controlled human evidence and FDA approval as Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
Research Supports
- FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
- Studied for effects on sexual desire and arousal via central melanocortin signaling, primarily MC4R
- Investigated, pre-approval, for male erectile function through a centrally mediated mechanism distinct from PDE5 inhibitors
- Used as a tool to study melanocortin receptor pharmacology in human sexual response
Observations Reported in Research
- RECONNECT Phase 3 trials found bremelanotide significantly improved validated measures of sexual desire and reduced related distress vs placebo (Kingsberg et al., 2019)
- Early studies found melanocortin agonism increased physiological and subjective sexual arousal in women (Diamond et al., 2006)
- Bremelanotide combined with sildenafil supported distinct, complementary mechanisms for erectile response in men (Diamond et al., 2005)
- Nausea and cardiovascular effects were common enough to require specific labeling precautions
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic cyclic melanocortin peptide; melanocortin receptor agonist; centrally acting sexual-function drug
PT-141 (Bremelanotide) is a synthetic cyclic melanocortin peptide developed from the Melanotan II research program. The family tree is worth understanding: α-MSH ↓ synthetic melanocortin analogues ↙︎ ↘︎ Afamelanotide / MT-I Melanotan II ↓ Bremelanotide / PT-141 Bremelanotide was specifically developed around the surprising sexual-response effects observed during Melanotan II research. It ultimately became a legitimate medicine: Vyleesi (bremelanotide) was FDA-approved in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women under the conditions specified in its labeling. So: PT-141 isn't simply an internet “libido peptide.” It's a melanocortin pharmacology story that progressed through controlled human trials and regulatory approval.
What Is PT-141?
Bremelanotide is a cyclic peptide derived structurally from Melanotan II. Unlike PDE5 inhibitors such as sildenafil, its principal sexual effects occur through central melanocortin signaling, rather than primarily through peripheral inhibition of phosphodiesterase-5. Its pharmacology involves melanocortin receptors, particularly: MC4R with additional activity at other melanocortin receptor subtypes. MC4R is strongly involved in: • central energy regulation • autonomic signaling • sexual behavior • motivational circuitry. That makes bremelanotide's mechanism fundamentally different from conventional erectile-dysfunction drugs.
What Are Researchers Studying?
Sexual desire
This became bremelanotide's principal clinical-development target. Melanocortin signaling in the central nervous system influences sexual motivation and arousal. Large Phase 3 studies eventually demonstrated statistically significant improvements in measures of sexual desire and reductions in distress associated with low sexual desire in appropriately selected premenopausal women. That evidence supported FDA approval.
Female sexual dysfunction
Bremelanotide has been studied specifically in acquired, generalized HSDD. This distinction matters. FDA approval does not mean: “approved libido enhancer for anyone.” The approved population and diagnostic criteria are substantially narrower. Aminodex should preserve the exact indication rather than reducing it to “increases female libido.”
Male erectile function
The male sexual-response story predates the HSDD program. Early controlled studies found that melanocortin agonism could produce penile erections in men with erectile dysfunction. This was scientifically important because the effect was centrally mediated, providing a mechanism distinct from PDE5 inhibitors. Bremelanotide was consequently studied in men both alone and alongside sildenafil. But male erectile dysfunction did not become its FDA-approved indication.
Central melanocortin signaling
Bremelanotide helped demonstrate that the melanocortin system participates directly in human sexual behavior. This provides an important link between Melanotan II, PT-141, MC4R, sexual arousal, and sexual motivation. The pigmentation pathway and sexual pathway overlap pharmacologically but are not identical. That explains why related melanocortin compounds can have very different clinical-development trajectories.
Melanocortin receptor pharmacology
The melanocortin family contains five receptors: MC1R → pigmentation; MC2R → ACTH/adrenal signaling; MC3R → metabolic/neural signaling; MC4R → appetite/autonomic/sexual signaling; MC5R → exocrine and other functions. These categories aren't absolute, but they're a useful orientation. Bremelanotide's sexual effects are associated particularly with central MC4R signaling, whereas afamelanotide's therapeutic effects center strongly on MC1R.
How Does It Work?
The simplified pathway: Bremelanotide ↓ central melanocortin receptors, particularly MC4R ↓ hypothalamic and broader neural signaling ↓ changes in sexual motivation/arousal circuitry ↓ increased sexual desire in appropriately selected patients. This differs substantially from: Sildenafil ↓ PDE5 inhibition ↓ increased cGMP signaling in penile vasculature. That mechanistic distinction is one of the most interesting things about PT-141.
What Does the Research Show?
Human research
Strong for the approved indication. Bremelanotide progressed through: • Early male sexual-response studies • Dose-finding studies • Female sexual-dysfunction trials • Large randomized Phase 3 trials • FDA regulatory review. This is not a compound whose popularity rests on rodent behavior or vendor anecdotes. But the evidence should still be indication-specific. Evidence for HSDD in premenopausal women doesn't establish benefit for: • Healthy people seeking increased libido • Male low sexual desire • Testosterone deficiency • SSRI sexual dysfunction • Postmenopausal HSDD • Every form of erectile dysfunction.
Animal research
Animal experiments were important in identifying melanocortin effects on: • sexual behavior • erection • grooming • appetite • central autonomic signaling. Those experiments helped lead from Melanotan II to the more targeted clinical development of bremelanotide.
In-vitro research
Cellular receptor assays have characterized bremelanotide's interactions with melanocortin receptors. These studies help explain both therapeutic effects and off-target/adverse effects. But the profile can rely primarily on human evidence because substantial clinical data exist.
Notable Studies
Bremelanotide for Female Sexual Dysfunction: Two Randomized Phase 3 Trials
humanThe RECONNECT studies evaluated subcutaneous bremelanotide in premenopausal women with acquired generalized HSDD. Bremelanotide significantly improved validated measures of sexual desire and reduced distress related to low sexual desire compared with placebo. These studies formed the central efficacy evidence supporting regulatory approval.
Limitations: Benefits were modest on average and apply to the studied HSDD population rather than generalized sexual enhancement. Nausea and other adverse effects were common, and cardiovascular effects required specific labeling precautions.
View publication →Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder
humanEarly clinical studies examined whether melanocortin agonism could increase physiological and subjective sexual arousal in women. Results helped establish proof of concept for central melanocortin modulation of female sexual response.
Limitations: Small early-phase study and older diagnostic framework; should not be treated as equivalent to later Phase 3 HSDD evidence.
View publication →Bremelanotide and Sildenafil in Men With Erectile Dysfunction
humanResearchers evaluated the combination of centrally acting bremelanotide with peripheral PDE5 inhibition in men with erectile dysfunction. The work supported the idea that melanocortin and PDE5 pathways can influence erectile response through distinct mechanisms.
Limitations: Small early-stage study. Bremelanotide did not ultimately receive FDA approval for male erectile dysfunction.
View publication →What We Still Don't Know
• Clinical utility outside the approved HSDD population • Long-term outcomes with extended intermittent use • Comparative effectiveness versus other HSDD treatments • Which patients are most likely to respond • Utility in postmenopausal women • Utility in male low-desire disorders • Role in medication-associated sexual dysfunction • Long-term cardiovascular outcomes • Whether particular melanocortin genotypes affect response • Whether research-market PT-141 products match pharmaceutical bremelanotide.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the PT-141 research with you.
Get the Aminodex PT-141 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Phase 3 RECONNECT trials of bremelanotide for acquired generalized HSDD in premenopausal women.
- Diamond LE et al. Early bremelanotide clinical research in female sexual arousal disorder.
- Diamond LE et al. Bremelanotide + sildenafil research in men with erectile dysfunction.
- FDA Vyleesi prescribing/approval documentation.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.